A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy ...